TERNS PHARMACEUTICALS INC.
-
USD
(-)
- 15 min delayed data - NASDAQ Stocks
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | TERN |
| ISIN: |
TERNS PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
TERNS PHARMACEUTICALS INC. - More news...
TERNS PHARMACEUTICALS INC. - More news...
- 03/20/2025 - 20:05 Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
- 02/26/2025 - 21:05 Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)
- 02/25/2025 - 13:05 Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
- 02/24/2025 - 21:05 Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
- 02/20/2025 - 21:05 Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors
- 02/05/2025 - 21:05 Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- 02/03/2025 - 21:05 Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- 01/08/2025 - 21:05 Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
- 01/02/2025 - 21:05 Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- 12/03/2024 - 12:00 Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia
- 12/02/2024 - 21:05 Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- 11/18/2024 - 21:05 Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
- 11/12/2024 - 21:05 Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates
- 11/06/2024 - 21:05 Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
- 10/07/2024 - 20:05 Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- 09/12/2024 - 23:00 Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- 09/11/2024 - 02:50 Terns Announces Pricing of Upsized $150.15 Million Public Offering
- 09/09/2024 - 20:01 Terns Announces Proposed Public Offering
- 09/09/2024 - 11:05 Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
- 08/05/2024 - 20:05 Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
- 08/01/2024 - 20:05 Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- 07/29/2024 - 20:05 Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
- 06/21/2024 - 22:30 Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
- 06/03/2024 - 20:10 Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
- 05/30/2024 - 12:05 Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
- 05/17/2024 - 20:05 Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
- 05/13/2024 - 12:05 Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
- 05/08/2024 - 20:05 Terns Pharmaceuticals Announces Leadership Changes
- 05/07/2024 - 20:05 Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
- 05/03/2024 - 20:05 Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
